Expensify Reports Q2 2025 Results with Revenue Growth

The latest update is out from Expensify ( (EXFY) ).

On August 7, 2025, Expensify announced its Q2 2025 results, highlighting a 31% increase in interchange derived from the Expensify Card, reaching $5.3 million. The company reported a revenue of $35.8 million, a 7% increase from the previous year, despite a net loss of $8.8 million. Expensify’s brand visibility increased significantly due to its presence in ‘F1® The Movie,’ leading to a 50% gain in brand awareness in target demographics. The company is expanding internationally, with the Expensify Card launching in the UK and EU, and support for over 10,000 banks worldwide. Expensify also enhanced its platform with multilingual support and additional billing options, aiming to capture a broader market. The company repurchased $3.0 million worth of shares and increased its full-year 2025 free cash flow guidance to $19.0 million – $23.0 million.

The most recent analyst rating on (EXFY) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Expensify stock, see the EXFY Stock Forecast page.

Spark’s Take on EXFY Stock

According to Spark, TipRanks’ AI Analyst, EXFY is a Neutral.

Expensify is currently facing financial challenges, with a negative P/E ratio and bearish technical indicators. Positive elements from the earnings call and corporate events offer some optimism, but these are outweighed by significant financial and market pressures.

To see Spark’s full report on EXFY stock, click here.

More about Expensify

Expensify, Inc. is a payments superapp that assists individuals and businesses globally in managing expenses, corporate cards, and bills. The company is focused on expanding its market reach, particularly in the UK, EU, and Canada, by offering the Expensify Card and supporting multiple languages and currencies.

Average Trading Volume: 736,144

Technical Sentiment Signal: Sell

Current Market Cap: $191.3M

Find detailed analytics on EXFY stock on TipRanks’ Stock Analysis page.